Drug intelligence / Profile preview

hepatitis B surface antigen + AS04

Development stage
Unknown
Lead developer
GSK
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

This is a combination vaccine consisting of **recombinant hepatitis B surface antigen** (HBsAg) as the antigen and **AS04** as the adjuvant. AS04 is made of 3-O-desacyl-4'-monophosphoryl lipid A (MPL), a detoxified derivative of lipid A from bacterial lipopolysaccharide, combined with aluminum salt. The vaccine is designed to induce protective immunity against hepatitis B virus with enhanced and more persistent antibody responses, particularly in populations with reduced vaccine responsiveness (such as patients with kidney disease). MPL stimulates the immune system through pattern recognition receptors, leading to activation of antigen-presenting cells and enhanced T-cell and B-cell responses. The vaccine is primarily indicated for the prophylaxis of hepatitis B virus infection and has demonstrated improved immunogenicity compared to formulations adjuvanted with aluminum salts alone[2][6][8].

Brand names
Fendrix
Other names
hepatitis B vaccine adjuvanted with AS04AS04-adjuvanted hepatitis B vaccineAS-04-adjuvanted hepatitis B vaccineAS 04-adjuvanted hepatitis B vaccine
02

Targets

LBP (Lipopolysaccharide-binding protein)TCR (T cell antigen receptor complex)CD14 (Monocyte differentiation antigen CD14)TLR4 (Toll-like receptor 4)

Beyond the preview

Go deeper on hepatitis B surface antigen + AS04.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on hepatitis B surface antigen + AS04.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call